Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beauty Health (SKIN) Cash & Equivalents (2020 - 2025)

Beauty Health (SKIN) has disclosed Cash & Equivalents for 6 consecutive years, with $219.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 38.87% to $219.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $219.4 million, a 38.87% decrease, with the full-year FY2024 number at $370.1 million, down 29.25% from a year prior.
  • Cash & Equivalents was $219.4 million for Q3 2025 at Beauty Health, up from $212.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $901.9 million in Q4 2021 to a low of $2.8 million in Q1 2021.
  • A 5-year average of $481.5 million and a median of $523.0 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 2874388.0% in 2021, then crashed 39.35% in 2025.
  • Beauty Health's Cash & Equivalents stood at $901.9 million in 2021, then crashed by 37.0% to $568.2 million in 2022, then dropped by 7.95% to $523.0 million in 2023, then dropped by 29.25% to $370.1 million in 2024, then plummeted by 40.71% to $219.4 million in 2025.
  • Per Business Quant, the three most recent readings for SKIN's Cash & Equivalents are $219.4 million (Q3 2025), $212.0 million (Q2 2025), and $373.0 million (Q1 2025).